|
Market Cap | 3.89M | EPS (ttm) | 0.65 |
P/E | 2.24 | EPS this Y | -89.70% |
Forward P/E | - | EPS next Y | 31.39% |
PEG | - | EPS past 5Y | 61.51% |
P/S | 0.32 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 81.52% |
Dividend | - | Sales Q/Q | - |
Insider Own | 7.89% | Inst Own | 10.60% |
Insider Trans | 0.00% | Inst Trans | -0.85% |
Short Float | 6.20% | Earnings | May 14/a |
Analyst Recom | 1.67 | Target Price | 37.50 |
Avg Volume | 272.08K | 52W Range | 1.51 - 14.75 |
|
|
|
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA. |
|
|
|
Market Cap | 6.09M | EPS (ttm) | -0.81 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -103.79% |
P/S | 0.20 | EPS next 5Y | - |
P/B | 0.27 | EPS Q/Q | -44.45% |
Dividend | - | Sales Q/Q | -40.56% |
Insider Own | 34.78% | Inst Own | 14.90% |
Insider Trans | 0.00% | Inst Trans | 233.06% |
Short Float | 0.19% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 8.00 |
Avg Volume | 19.66K | 52W Range | 0.64 - 2.39 |
|
|
|
Twin Vee PowerCats Co. engages in the design, manufacture, and sale of recreational and commercial power catamaran boats. The firm is focused on designing and developing its products under the ELECTRA Power Sports brand. It operates through the following segments: Gas-Powered Boats, Electric Boat and Development, and Franchise. The Gas-Powered Boats segment manufactures boats that use fuel. The Electric Boat and Development segment designs fully electric boats through Forza X1 Inc. The Franchise segment deals with developing a standard product offering that is sold for franchise. The company was founded by Roger Dunshee in 1996 and is headquartered in Fort Pierce, FL. |
|
|
|
Market Cap | 32.85M | EPS (ttm) | -42.75 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | 62.30% |
P/S | 16.67 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 94.28% |
Dividend | - | Sales Q/Q | -28.34% |
Insider Own | 8.70% | Inst Own | 13.10% |
Insider Trans | 11.73% | Inst Trans | -46.15% |
Short Float | 0.82% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 32.00 |
Avg Volume | 63.36K | 52W Range | 1.92 - 398.40 |
|
|
|
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mehra Raj | See Remarks | Dec 01 '23 | Buy | 1.32 | 75,757 | 99,999 | 185,142 | Dec 01 04:16 PM | Golembiewski Michael Joseph | Chief Financial Officer | Nov 30 '23 | Buy | 1.21 | 83,000 | 100,222 | 86,450 | Dec 01 04:16 PM |
|
|
| |
|
Market Cap | 27.69M | EPS (ttm) | -4.21 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 22.70 | EPS next 5Y | - |
P/B | - | EPS Q/Q | -44077.42% |
Dividend | - | Sales Q/Q | - |
Insider Own | 37.49% | Inst Own | 7.01% |
Insider Trans | 0.00% | Inst Trans | 6.72% |
Short Float | 2.61% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 1.17M | 52W Range | 0.90 - 18.50 |
|
|
|
Zapata Computing Holdings, Inc. operates as a generative AI company. It provides data science and engineering techniques for solutions on an industrial scale. The company was founded by Christopher Savoie, Alan Aspuru-Guzik, Yudong Cao, Jonathan Olson, Peter Johnson, and Jonathan Romero-Fontalvo in 2017 and is headquartered in Boston, MA. |
|
|
|
Market Cap | 3.25M | EPS (ttm) | -27.34 |
P/E | - | EPS this Y | 71.22% |
Forward P/E | - | EPS next Y | 17.36% |
PEG | - | EPS past 5Y | 34.89% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 63.17% |
Dividend | - | Sales Q/Q | - |
Insider Own | 0.23% | Inst Own | 23.89% |
Insider Trans | 0.00% | Inst Trans | 112.18% |
Short Float | 2.84% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 20.00 |
Avg Volume | 1.47M | 52W Range | 2.08 - 44.80 |
|
|
|
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX. |
|
| |
|
Market Cap | 37.49M | EPS (ttm) | -1.00 |
P/E | - | EPS this Y | 22.95% |
Forward P/E | - | EPS next Y | 40.71% |
PEG | - | EPS past 5Y | 0.80% |
P/S | 1.26 | EPS next 5Y | - |
P/B | 0.89 | EPS Q/Q | -11.97% |
Dividend | - | Sales Q/Q | 2.09% |
Insider Own | 5.49% | Inst Own | 39.59% |
Insider Trans | 38.05% | Inst Trans | -2.20% |
Short Float | 10.69% | Earnings | May 13/b |
Analyst Recom | 1.80 | Target Price | 1.35 |
Avg Volume | 643.31K | 52W Range | 0.39 - 3.57 |
|
|
|
Akoustis Technologies, Inc. is a filter solutions company, which engages in the development, design, and manufacture of radio frequency (RF) filter products. It operates through the Foundry Fabrication Services and RF Filters segments. The Foundry Fabrication Services segment is composed of engineering review services and STC-MEMS foundry services. The RF Filters segment includes amplifier and filter product sales, and grant revenue. The company was founded by Jeffrey B. Shealy in 2014 and is headquartered in Huntersville, NC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Shealy Jeffrey B. | Chief Executive Officer | Jan 29 '24 | Buy | 0.50 | 1,310,000 | 655,000 | 2,222,775 | Jan 31 06:39 PM | Aichele David | EVP of Business Development | Jan 29 '24 | Buy | 0.50 | 80,000 | 40,000 | 334,622 | Jan 31 06:39 PM | Boller Kenneth | CFO | Jan 29 '24 | Buy | 0.50 | 60,000 | 30,000 | 214,957 | Jan 31 06:39 PM | Geiss Arthur | Director | Jan 29 '24 | Buy | 0.50 | 50,000 | 25,000 | 415,924 | Jan 31 06:40 PM | Aichele David | EVP of Business Development | Dec 18 '23 | Sale | 0.72 | 1,500 | 1,083 | 254,622 | Dec 20 05:03 PM |
|
|
|
|
Market Cap | 10.31M | EPS (ttm) | - |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -32.60% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | -13.12% |
Dividend | - | Sales Q/Q | -80.94% |
Insider Own | 57.02% | Inst Own | 8.96% |
Insider Trans | 0.00% | Inst Trans | -0.67% |
Short Float | 0.33% | Earnings | - |
Analyst Recom | 1.00 | Target Price | 1.50 |
Avg Volume | 146.82K | 52W Range | 0.36 - 1.98 |
|
|
|
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark. |
|
| |
|
Market Cap | 11.34M | EPS (ttm) | -102.71 |
P/E | - | EPS this Y | 82.97% |
Forward P/E | - | EPS next Y | 23.39% |
PEG | - | EPS past 5Y | -49.91% |
P/S | 0.21 | EPS next 5Y | - |
P/B | - | EPS Q/Q | 85.43% |
Dividend | - | Sales Q/Q | -70.54% |
Insider Own | 0.00% | Inst Own | 6.42% |
Insider Trans | - | Inst Trans | - |
Short Float | 1.14% | Earnings | May 15/b |
Analyst Recom | 2.00 | Target Price | 53.28 |
Avg Volume | 1.53M | 52W Range | 1.45 - 170.40 |
|
|
|
22nd Century Group, Inc. is a biotechnology company, which engages in the business of tobacco harm reduction, reduced nicotine tobacco, and improvement of health and wellness through plant science. It operates through the Tobacco and Hemp/Cannabis segments. The Tobacco segment manufactures branded filtered cigars and cigarettes. The Hemp/Cannabis segment focuses on the bulk ingredient distillate or isolate. The company was founded on September 12, 2005 and is headquartered in Buffalo, NY. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Arno Andrew | Director | Jan 05 '24 | Buy | 0.17 | 100,000 | 17,490 | 100,000 | Jan 08 08:04 PM | FIRESTONE LAWRENCE | Chief Executive Officer | Jan 04 '24 | Buy | 0.17 | 100,000 | 17,360 | 100,000 | Jan 05 04:32 PM |
|
|
|
|
Market Cap | 1.11B | EPS (ttm) | 0.18 |
P/E | 36.29 | EPS this Y | -16.61% |
Forward P/E | 8.96 | EPS next Y | 33.59% |
PEG | 2.84 | EPS past 5Y | 19.43% |
P/S | 2.33 | EPS next 5Y | 12.80% |
P/B | 1.99 | EPS Q/Q | -71.19% |
Dividend | - | Sales Q/Q | -13.59% |
Insider Own | 3.70% | Inst Own | 118.14% |
Insider Trans | -0.28% | Inst Trans | -7.55% |
Short Float | 13.77% | Earnings | May 07/a |
Analyst Recom | 1.67 | Target Price | 13.70 |
Avg Volume | 4.50M | 52W Range | 6.66 - 28.34 |
|
|
May-14-24 01:26PM
|
Investors in Shoals Technologies Group, Inc. Should Contact Levi & Korsinsky Before May 21, 2024 to Discuss Your Rights SHLS
(GlobeNewswire) |
May-13-24 05:45AM
|
Shoals Technologies Group, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 21, 2024 to Discuss Your Rights - SHLS
(PR Newswire) |
May-09-24 11:58AM
|
Barclays Adjusts Shoals Technologies Group's Price Target to $12 From $13, Keeps Equalweight Rating
(MT Newswires) |
08:00AM
|
Shoals Technologies Group Expands Leadership Team with Key Appointments in International Business and Investor Relations
(GlobeNewswire) |
05:14AM
|
Truist Adjusts Price Target on Shoals Technologies to $12 From $20, Maintains Buy Rating
(MT Newswires) |
May-08-24 02:06PM
|
7 Ignored Tech Stocks That Deserve Their Share of the Spotlight
(InvestorPlace) -14.66% |
01:54PM
|
Analyst Report: Shoals Technologies Group, Inc.
(Morningstar Research) |
12:11PM
|
Shoals Technologies Group, Inc. (NASDAQ:SHLS) Q1 2024 Earnings Call Transcript
(Insider Monkey) |
10:15AM
|
Mizuho Adjusts Shoals Technologies Group's Price Target to $13 From $16, Keeps Buy Rating
(MT Newswires) |
08:58AM
|
Oppenheimer Cuts Shoals Technologies Group Price Target to $14 From $17, Maintains Outperform Rating
(MT Newswires) |
|
Shoals Technologies Group, Inc. provides electrical balance of system solutions for solar energy projects. Its EBOS components include cable assemblies, inline fuses, combiners, disconnects, recombiners, wireless monitoring systems, junction boxes, transition enclosures and splice boxes. The company was founded by Dean Solon in November 1996 and is headquartered in Portland, TN. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Peetz Mehgan | General Counsel | Mar 08 '24 | Sale | 13.04 | 3,160 | 41,206 | 105,201 | Mar 11 04:37 PM | TOLNAR JEFFERY | President | Mar 08 '24 | Sale | 13.04 | 2,750 | 35,860 | 96,391 | Mar 11 04:37 PM | Lund Inez | Chief Accounting Officer | Mar 08 '24 | Sale | 13.05 | 1,940 | 25,317 | 21,577 | Mar 11 04:37 PM | Bardos Dominic | Chief Financial Officer | Dec 05 '23 | Sale | 14.24 | 4,200 | 59,808 | 66,925 | Dec 06 04:28 PM | Peetz Mehgan | General Counsel | Dec 05 '23 | Sale | 14.21 | 3,310 | 47,035 | 78,075 | Dec 06 04:29 PM |
|
|
|
|
Market Cap | 3.72M | EPS (ttm) | -12.96 |
P/E | - | EPS this Y | 62.43% |
Forward P/E | - | EPS next Y | 44.97% |
PEG | - | EPS past 5Y | 63.34% |
P/S | 5.55 | EPS next 5Y | - |
P/B | 0.66 | EPS Q/Q | 30.36% |
Dividend | - | Sales Q/Q | 21.62% |
Insider Own | 4.61% | Inst Own | 3.02% |
Insider Trans | 8.37% | Inst Trans | - |
Short Float | 2.66% | Earnings | May 13/a |
Analyst Recom | 1.00 | Target Price | 4.00 |
Avg Volume | 541.45K | 52W Range | 1.49 - 14.44 |
|
|
|
Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain's ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded in 2014 and is headquartered in Newtown, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
ANDREEFF DANE | President and CEO | Dec 14 '23 | Buy | 8.10 | 5,000 | 40,475 | 16,512 | Dec 15 07:00 AM | ANDREEFF DANE | President and CEO | Dec 01 '23 | Buy | 6.45 | 2,006 | 12,935 | 13,685 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Nov 30 '23 | Buy | 6.37 | 2,000 | 12,741 | 12,551 | Dec 04 08:30 AM | ANDREEFF DANE | President and CEO | Aug 30 '23 | Buy | 7.64 | 5,000 | 38,212 | 11,420 | Aug 30 08:42 PM | ANDREEFF DANE | President and CEO | Aug 28 '23 | Buy | 6.37 | 5,078 | 32,339 | 8,774 | Aug 30 08:42 PM |
|
|
|